
Instil Bio (TIL) Stock Forecast & Price Target
Instil Bio (TIL) Analyst Ratings
Bulls say
Instil Bio Inc., a clinical-stage biopharmaceutical company, is experiencing significant momentum due to its innovative pipeline of tumor infiltrating lymphocyte (TIL) therapies, particularly with the promising data emerging from the HARMONi-2 study, which previously resulted in a substantial stock price surge. The potential for upside remains strong, as the company is strategically positioned to expand its technology into additional indications, bolstered by an estimated firm value of approximately $884 million derived from discounted cash flow analysis, indicating robust future growth prospects. Furthermore, Instil Bio's unique approach to combining checkpoint inhibition with anti-angiogenesis therapies places it at the forefront of the biopharmaceutical landscape, enhancing its competitive advantage and increasing confidence among investors.
Bears say
Instil Bio Inc reported a substantial net loss of $1.82 per share in the fourth quarter of 2024 and projects an alarming increase to $11.51 per share for the full year of 2025, reflecting a significant deterioration in financial performance. The company faces considerable risks, including potential delays in clinical advancement of key candidates and the possibility of unfavorable clinical data, particularly concerning AXN-2510 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Additionally, there is a looming concern regarding medium- to long-term dilution risk, which could adversely impact shareholder value.
This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.
Instil Bio (TIL) Analyst Forecast & Price Prediction
Start investing in Instil Bio (TIL)
Order type
Buy in
Order amount
Est. shares
0 shares